Nocturia, Overactive Bladder Improved With PTNS

Percutaneous tibial nerve stimulation (PTNS) improves overactive bladder (OAB) symptoms and decreases the number of nocturia episodes in patients who do not respond well to medication therapy, new study findings suggest. In a retrospective study of 183 female patients (mean age 74 years; 83% white) treated at a urogynecology center, 12 weeks of PTNS (30 minutes per week) reduced voiding frequency by 1 hour, nocturia episodes by 0.8, and urge incontinence by 10 episodes per week, Shilpa Iyer, MD, of the University of Chicago, and colleagues reported in International Urogynecology Journal. Previously, patients voided every 1.6 hours, awoke 2 to 3 times nightly to void, and averaged 3 urge incontinence episodes daily. Read more.

Source: Renal & Urology News, December 12, 2018

LABORIE Medical Technologies and Cogentix Medical Announce Completion of Acquisition

LABORIE Medical Technologies (“LABORIE”) and Cogentix Medical, Inc. (NASDAQ: CGNT) (“Cogentix”) today announced the completion of the acquisition by LABORIE of Cogentix through LABORIE’S affiliate Camden Merger Sub, Inc. (“Merger Sub”), a wholly owned subsidiary of LM US Parent, Inc. (“Parent”). After the previously announced completion of the tender offer for all of the outstanding shares of Cogentix, LABORIE completed the second step merger under Delaware law, resulting in Cogentix becoming a wholly owned subsidiary of Parent. At the effective time of the merger, all shares of Cogentix common stock not purchased in the tender offer (excluding those shares for which holders properly exercised appraisal rights under Delaware law and those held by Cogentix) were converted into the right to receive US$3.85, net to the seller in cash without interest thereon and subject to any required withholding tax, which is the same price that was paid for shares of Cogentix common stock purchased in the tender offer. Cogentix common stock will no longer be listed on the Nasdaq Capital Market or any other securities exchange. Read more.

Source: The Virginian-Pilot, April 23, 2018

Nonpharmacologic Therapy Ups Sleep Quality in Women With Nocturia

Both tibial nerve stimulation (TNS) and pelvic floor muscle training (PFMT) can improve sleep quality in women with nocturia, according to new study findings. In a randomized trial, 40 women with self-reported nocturia were blindly assigned to transcutaneous electrical TNS or PFMT with behavioral therapy for 30 minutes each week for 3 months. PFMT inhibits detrusor contraction, and TNS eases lower urinary tract symptoms. Women with neurogenic bladder or on antimuscarinic or antidiuretic therapy were among the excluded patients. Read more.

Source: Renal and Urology News, April 11, 2018

Percutaneous Tibial Nerve Stimulation (PTNS)

percutaneous tibial nerve stimulation female patient

A female patient is using Percutaneous Tibial Nerve Stimulation (PTNS) to help control her urinary incontinence. An electrode is placed only at the ankle area.

Percutaneous Tibial Nerve Stimuation (PTNS) is a low-risk, non-surgical treatment. PTNS works by indirectly providing electrical stimulation to the nerves responsible for bladder and pelvic floor function. During PTNS treatment, the patient’s foot is comfortably elevated and supported. Also during treatment, a slim needle electrode is placed near the nerve at the ankle known as the tibial nerve. A device known as the Urgent PC Stimulator is connected to the electrode and sends mild electrical pulses to the tibial nerve. These impulses travel to the sacral nerve plexus, the group of nerves at the base of the spine responsible for bladder function. Continue reading→